litlas
Log inCreate account

David T. Dexter

Active 1986–2025

76
Papers
20,925
Citations
62
h-index
74
i10-index

Citations

Citations per year for David T. Dexter1986: 3 citations1987: 2 citations1988: 4 citations1989: 22 citations1990: 36 citations1991: 61 citations1992: 98 citations1993: 65 citations1994: 126 citations1995: 101 citations1996: 116 citations1997: 137 citations1998: 132 citations1999: 146 citations2000: 137 citations2001: 119 citations2002: 161 citations2003: 166 citations2004: 184 citations2005: 166 citations2006: 154 citations2007: 180 citations2008: 200 citations2009: 183 citations2010: 167 citations2011: 243 citations2012: 181 citations2013: 244 citations2014: 238 citations2015: 225 citations2016: 207 citations2017: 231 citations2018: 266 citations2019: 638 citations2020: 682 citations2021: 714 citations2022: 567 citations2023: 449 citations2024: 605 citations2025: 300 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,208 citing papers, 23.3% of this breakdownUnited Kingdom: 805 citing papers, 8.5% of this breakdownChina: 804 citing papers, 8.5% of this breakdownGermany: 517 citing papers, 5.5% of this breakdownItaly: 473 citing papers, 5% of this breakdownIndia: 427 citing papers, 4.5% of this breakdownSpain: 331 citing papers, 3.5% of this breakdownAustralia: 315 citing papers, 3.3% of this breakdownCanada: 296 citing papers, 3.1% of this breakdownFrance: 292 citing papers, 3.1% of this breakdownJapan: 237 citing papers, 2.5% of this breakdownSouth Korea: 161 citing papers, 1.7% of this breakdown
0%23.3%Other 27.5%

Institutions

Fields

  • Medicine56.5%
  • Biochemistry, Genetics and Molecular Biology19.6%
  • Neuroscience14%
  • Nursing3.4%
  • Agricultural and Biological Sciences1.7%
  • Materials Science1.1%
  • Other3.7%

Topics

  • Parkinson's Disease Mechanisms and Treatments14.2%
  • Alzheimer's disease research and treatments4.9%
  • Neuroinflammation and Neurodegeneration Mechanisms3.4%
  • Neurological disorders and treatments3.2%
  • Neurological diseases and metabolism3.2%
  • Nuclear Receptors and Signaling3.1%
  • Other68%

Coauthors

All papers

Open in search
  1. Trial of Deferiprone in Parkinson’s Disease

    Authors: David Devos, Julien Labreuche, Olivier Rascol, Jean‐Christophe Corvol, Alain Duhamel, Pauline Guyon Delannoy, Werner Poewe, Yaroslau Compta, Nicola Pavese, Evžen Růžička, Petr Dušek, Bart Post, Bastiaan R. Bloem, Daniela Berg, Walter Maetzler, Markus Otto, Marie‐Odile Habert, Stéphane Lehéricy, Joaquim J. Ferreira, Richard Dodel, Christine Tranchant, Alexandre Eusébio, Stéphane Thobois, Ana Marquès, Wassilios G. Meissner, Fabienne Ory‐Magne, Uwe Walter, Rob M.A. de Bie, Miguel Gago, Dolores Vilas, Jaime Kulisevsky, Cristina Januário, Miguel Vilhena Soares Coelho, Stefanie Behnke, Paul Worth, Klaus Seppi, Thavarak Ouk, Camille Potey, Céline C. Leclercq, Romain Viard, Grégory Kuchcinski, Renaud Lopes, Jean‐Pierre Pruvo, Pascal Pigny, Guillaume Garçon, O. Simonin, Jessica Carpentier, Anne‐Sophie Rolland, Dag Nyholm, Christoph Scherfler, Jean‐François Mangin, Marie Chupin, Régis Bordet, David T. Dexter, Caroline Fradette, Michael Spino, Fernando Tricta, Scott Ayton, Ashley I. Bush, Jean-Christophe Devedjian, James A. Duce, Ioav Cabantchik, Luc Defebvre, Dominique Deplanque, Caroline Moreau - New England Journal of Medicine 2022 cited by 223

  2. Mitochondrial Complex I Deficiency in Parkinson's Disease

    Authors: Anthony H.V. Schapira, Jonathan M. Cooper, David T. Dexter, J. B. Clark, Peter Jenner, C. D. Marsden - Journal of Neurochemistry 1990 cited by 2,276

  3. ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE METALS IN PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA

    Authors: David T. Dexter, A. Carayon, F. Javoy‐Agid, Yves Agid, F. R. Wells, S. E. Daniel, Andrew J. Lees, Peter Jenner, C. D. Marsden - Brain 1991 cited by 1,044

  4. Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease

    Authors: Laurie Robak, Iris E. Jansen, Jeroen van Rooij, André G. Uitterlinden, Robert Kraaij, Joseph Jankovic, Peter Heutink, Joshua Shulman, Mike A. Nalls, Vincent Plagnol, Dena G Hernandez, Manu Sharma, Una‐Marie Sheerin, Mohamad Saad, Javier Simón‐Sánchez, Claudia Schulte, Suzanne Lesage, Sigurlaug Sveinbjörnsdóttir, Sampath Arepalli, Roger A. Barker, Yoav Ben-, Henk W. Berendse, Daniela Berg, Kailash P. Bhatia, Rob M.A. de Bie, Alessandro Biffi, Bas Bloem, Zoltán Bochdanovits, Michael von Bonin, José Brás, Kathrin Brockmann, Janet Brooks, David J. Burn, Elisa Majounie, Gavin Charlesworth, Codrin Lungu, Honglei Chen, Patrick F. Chinnery, Sean Chong, Carl E Clarke, Mark Cookson, Jonathan M. Cooper, Jean‐Christophe Corvol, Carl Counsell, Philippe Damier, Jean‐François Dartigues, Panos Deloukas, Günther Deuschl, David T. Dexter, Karin D. van Dijk, Allissa Dillman, F. Durif, Alexandra Dürr, Sarah Edkins, Jonathan Evans, Thomas Foltynie, Jing Dong, Michelle Gardner, J. Raphael Gibbs, Alison Goate, Emma Gray, Rita Guerreiro, Clare Harris, Jacobus J. van Hilten, Albert Hofman, Albert R. Hollenbeck, Janice L. Holton, Michele Hu, Xuemei Huang, Isabel Wurster, Walter Mätzler, Gavin Hudson, Sarah Hunt, Johanna Huttenlocher, Thomas Illig, Pálmi V. Jónsson, Jean‐Charles Lambert, Cordelia Langford, Andrew J. Lees, Peter Lichtner, Patricia Limousin, Grisel Lopez, Delia Lorenz, Codrin Lungu, Alisdair McNeill, Catriona Moorby, Matthew Moore, Huw R. Morris, Karen Morrison, Valentina Escott‐Price, Ese Mudanohwo, Sean S. O’Sullivan, Justin Pearson, Joel S. Perlmutter, Hjörvar Pétursson, Pierre Pollak, Bart Post, Simon Potter, Bernard Ravina, Tamás Révész and 40 more - Brain 2017 cited by 451

  5. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

    Authors: Antonio Martín‐Bastida, Roberta J. Ward, Rexford D. Newbould, Paola Piccini, David Sharp, Christina Kabba, Maneesh C. Patel, Michael Spino, John Connelly, Fernando Tricta, Robert R. Crichton, David T. Dexter - Scientific Reports 2017 cited by 368

  6. Parkinson disease: from pathology to molecular disease mechanisms

    Authors: David T. Dexter, Peter Jenner - Free Radical Biology and Medicine 2013 cited by 709

  7. Iron, Neuroinflammation and Neurodegeneration

    Authors: Roberta J. Ward, David T. Dexter, Robert R. Crichton - International Journal of Molecular Sciences 2022 cited by 137

  8. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

    Authors: Jeswinder Sian, David T. Dexter, Andrew J. Lees, Susan E. Daniel, Yves Agid, France Javoy‐Agid, Peter Jenner, C. D. Marsden - Annals of Neurology 1994 cited by 1,153

  9. Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

    Authors: David T. Dexter, F. R. Wells, Alyssa Lee, F. Agid, Yves Agid, P. Jenner, C. D. Marsden - Journal of Neurochemistry 1989 cited by 1,148

  10. Transmission of multiple system atrophy prions to transgenic mice

    Authors: Joel C. Watts, Kurt Giles, Abby Oehler, Lefkos Middleton, David T. Dexter, Steve Gentleman, Stephen J. DeArmond, Stanley B. Prusiner - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 453

  11. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition

    Authors: Emilie Croisier, Linda Moran, David T. Dexter, Ronald KB Pearce, Manuel B. Graeber - Journal of Neuroinflammation 2005 cited by 432

  12. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease

    Authors: David T. Dexter, Christopher Carter, F. R. Wells, F. Javoy‐Agid, Yves Agid, Andrew J. Lees, Peter Jenner, C. D. Marsden - Journal of Neurochemistry 1989 cited by 1,400

  13. GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop

    Authors: Roger A. Barker, Anders Björklund, Don M. Gash, Alan Whone, Amber D. Van Laar, Jeffrey H. Kordower, Krystof S. Bankiewicz, Karl Kieburtz, Märt Saarma, Sigrid Booms, Henri J. Huttunen, Adrian P. Kells, Massimo S. Fiandaca, A. Jon Stoessl, David Eidelberg, Howard J. Federoff, Merja H. Voutilainen, David T. Dexter, Jamie L. Eberling, Patrik Brundin, Lyndsey Isaacs, Leah Mursaleen, Eros Bresolin, Camille Carroll, Alasdair Coles, Brian Fiske, Helen Matthews, Codrin Lungu, Richard Wyse, Simon Stott, Anthony E. Lang - Journal of Parkinson s Disease 2020 cited by 136

  14. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease

    Authors: Virginia Zbarsky, Krishna P. Datla, Shabnam Parkar, Deepal K. Rai, Okezie I. Aruoma, David T. Dexter - Free Radical Research 2005 cited by 460

  15. INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN

    Authors: David T. Dexter, F. R. Wells, F. Agid, Yves Agid, Andrew J. Lees, Peter Jenner, C. D. Marsden - The Lancet 1987 cited by 967

  16. Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?

    Authors: Ian F. Harrison, David T. Dexter - Pharmacology & Therapeutics 2013 cited by 225

  17. Iron as a therapeutic target for Parkinson's disease

    Authors: Caroline Moreau, James A. Duce, Olivier Rascol, Jean‐Christophe Devedjian, Daniela Berg, David T. Dexter, Z. Ioav Cabantchik, Ashley I. Bush, David Devos, the FAIRPARK‐II study group - Movement Disorders 2018 cited by 126

  18. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease

    Authors: Krishna P. Datla, M. Christidou, William W. Widmer, Harcharan K. Rooprai, David T. Dexter - Neuroreport 2001 cited by 223

  19. Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease

    Authors: Ilse S. Pienaar, Cecilia Heyne Lee, Joanna L. Elson, Louisa McGuinness, Stephen M. Gentleman, Raj N. Kalaria, David T. Dexter - Neurobiology of Disease 2014 cited by 125

  20. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia

    Authors: David T. Dexter, Peter Jenner, Anthony H.V. Schapira, C. D. Marsden - Annals of Neurology 1992 cited by 290

  21. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6‐hydroxydopamine model of Parkinson’s disease

    Authors: L Marinova-Mutafchieva, Mona Sadeghian, Lauren Broom, John B. Davis, Andrew D. Medhurst, David T. Dexter - Journal of Neurochemistry 2009 cited by 216

  22. Pathological histone acetylation in Parkinson’s disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition

    Authors: Ian F. Harrison, Andrew D. Smith, David T. Dexter - Neuroscience Letters 2017 cited by 125

  23. Brain iron metabolism and its perturbation in neurological diseases

    Authors: Robert R. Crichton, David T. Dexter, Roberta J. Ward - Journal of Neural Transmission 2010 cited by 249

  24. Iron and the immune system

    Authors: Roberta J. Ward, Robert R. Crichton, Deanna L. Taylor, Laura Corte, Surjit Kaila Srai, David T. Dexter - Journal of Neural Transmission 2010 cited by 143